Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I

The approval covers pediatric patients without a matched sibling donor for stem cell transplant

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

New diabetes drug UBT251 shows strong phase 2 results in China

Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility

The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India